Jiangsu Lianhuan Pharmaceutical Co., Ltd. (SHA:600513)
China · Delayed Price · Currency is CNY 15.09
+0.28 (1.89%)
Sep 30, 2026, 3:00 PM CST
SHA:600513 Revenue
Jiangsu Lianhuan Pharmaceutical had revenue of 760.19M CNY in the quarter ending June 30, 2026, with 15.59% growth. This brings the company's revenue in the last twelve months to 3.00B, up 29.23% year-over-year. In the year 2025, Jiangsu Lianhuan Pharmaceutical had annual revenue of 2.71B with 25.52% growth.
Revenue (ttm)
3.00B
Revenue Growth
+29.23%
P/S Ratio
1.44
Revenue / Employee
1.41M
Employees
2,131
Market Cap
4.31B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.71B | 551.40M | 25.52% |
| Dec 31, 2024 | 2.16B | -13.64M | -0.63% |
| Dec 31, 2023 | 2.17B | 218.94M | 11.20% |
| Dec 31, 2022 | 1.96B | 309.34M | 18.80% |
| Dec 31, 2021 | 1.65B | 259.78M | 18.74% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Jianmin Pharmaceutical Group | 3.18B |
| Henan Taloph Pharmaceutical Stock Co.,Ltd | 1.73B |
| Zhejiang AngLiKang Pharmaceutical CO.,LTD. | 1.33B |
| Tianjin Lisheng Pharmaceutical | 1.30B |
| LanZhou Foci Pharmaceutical | 926.49M |
| Harbin Medisan Pharmaceutical | 805.09M |
| Shandong Wohua Pharmaceutical | 784.94M |
| Newland Pharmaceutical | 710.55M |